HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating from a Chinese innovative pharmaceutical company's independent R&D.

FirstWord Pharma's 2026 list aggregates core pipeline assets from the world's leading pharmaceutical companies. Alongside ivonescimab, the list highlights transformative therapies such as Eli Lilly's Alzheimer's treatment Kisunla, AstraZeneca/Daiichi Sankyo's ADC Datroway, Novartis' antisense oligonucleotide Pelacarsen, and Moderna/Merck's personalized mRNA cancer vaccine intesmeran autogene. Other featured assets include Gilead Sciences/Arcellx's CAR-T therapy anito-cel, Roche's oral SERD Giredestrant, and next-generation metabolic therapies from Novo Nordisk and Pfizer.

Akeso maintains a global operational outlook, with a steadfast commitment to addressing unmet clinical needs. The company consistently refines its research, development, and clinical strategies, while broadening its multidimensional drug technology innovation platform. As it advances its global "IO 2.0+" strategy, Akeso is accelerating the worldwide development of cutting-edge therapies in areas such as autoimmune and neurological disorders. Through open collaboration, the company integrates global advantages and resources, continually strengthening its core international competitiveness, ultimately advancing innovative medicines of Chinese origin for the benefit of patients worldwide.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

Goldman Sachs published a research report anticipating that investors' initial reaction to Meta (META.US)'s 4Q25 financial results will be slightly positive, mainly based on strong4Q25 revenue trends, better-than-expected 1Q26 revenue guidance and forward-looking operating expense/ capital expenditure guidance.

Although the expense guidance is higher than the broker's previous estimation, it remains slightly below market concerns.

Therefore, the broker rated Meta at Buy, with a target price of US$815.
~


AASTOCKS Financial News
Website: www.aastocks.com

SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.

Under the agreement, Sinorda Biomedicine will leverage WuXi Biologics' extensive experience and manufacturing capabilities in biologics development and manufacturing to advance SND006's preclinical pharmacology studies and clinical supply, accelerating the Investigational New Drug (IND) application process. SND006 is an innovative bispecific antibody independently developed by Sinorda Biomedicine, for which the company holds worldwide rights. Sinorda Biomedicine has completed in vitro functional validation studies of SND006 and plans to submit IND applications to both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in 2026. In the future, the two companies will further expand their collaboration around Sinorda Biomedicine's potential pipeline, including multiple integrated projects spanning from molecule discovery to clinical manufacturing.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Over the past decade, we have accumulated experience across hundreds of projects in bispecific and multispecific antibodies, which have become one of our fastest‑growing areas. We are pleased to accelerate the development and manufacturing of Sinorda Biomedicine's innovative bispecific antibody SND006 through our integrated technology platforms and comprehensive capabilities. Looking ahead, we will continue accelerating and transforming biologics discovery, development and manufacturing to empower global partners and make innovative biologics more accessible and affordable for patients worldwide."

Dr. Pingsheng Hu, Chairman and General Manager of Sinorda Biomedicine, commented, "SND006 is a potentially best-in-class innovative bispecific antibody discovered and developed by Sinorda Biomedicine, with the potential to deliver breakthroughs in the treatment of gastrointestinal and multiple autoimmune diseases. WuXi Biologics is a global leader in CRDMO services, offering truly end‑to‑end solutions underpinned by accumulated know-how, comprehensive technology platforms, and a strong track record—particularly in the development and manufacturing of bispecific antibodies. We believe this collaboration will accelerate the IND filings of our innovative biologics in China and worldwide, address unmet medical needs in autoimmune diseases, and ultimately bring safe and effective therapies to patients."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

About Sinorda Biomedicine

Sinorda Biomedicine was established in 2010 and is a biomedical innovation company in the commercialization stage. The company focuses on the research and development and industrialization of innovative drugs for digestive tract diseases, tumor immunity and autoimmune diseases. It has a bioinnovative drug technology platform, a clinical medical R&D platform and an experienced international R&D team, with successful experience in innovative drug applications in China, Europe, America and other countries.

Linaprazan glureta (X842), the company's self-developed class 1.1 new drug for treatment of gastric acid-related diseases, has been successfully approved for commercialization and industrialization. The sentinel lymph node T cell project for solid tumor treatment has clinical IIT research results for various tumors. In addition, the company has a number of early-stage product pipelines, including bispecific antibodies for the treatment of autoimmune disease IBD.

The company has developed rapidly through extensive cooperation with domestic and foreign pharmaceutical companies and R&D institutions, and is committed to becoming the most valuable innovative pharmaceutical enterprise in China.

WuXi Biologics Contacts

Business
[email protected]

Media
[email protected]

Chinese regulators have approved the procurement of Nvidia (NVDA.US) H200 AI chips by three tech giants: BABA-W (09988.HK), TENCENT (00700.HK), and ByteDance, according to foreign media reports.

If the news is confirmed by official sources and the relevant companies, it will have a positive impact on TENCENT, BABA-W, and the overall Chinese internet industry, Citi said in its report.

Particularly, the report highlighted that TENCENT will be the biggest beneficiary as its management mentioned during an earnings call that leasing GPU computing power could be an alternative in the event of direct procurement restrictions. That said, the report also warned that there is a risk of increased capital expenditure in 2026.

Citi's preference for the AI industry: TENCENT > BABA-W > BIDU-SW (09888.HK).
~



AAStocks Financial News
Web Site: www.aastocks.com

Tesla (TSLA.US) CEO Elon Musk said that the Company will gradually cease production of new Model S and Model Y vehicles next quarter.

The space in the California factory currently used for producing Model S and Model X will be repurposed for the manufacturing of Optimus robots, further advancing the Company's transition from EV operations to the robotics sector.

The above decision is part of the Company's transformation towards future autonomous driving, Musk added. The Company aims to produce 1 million Optimus robots annually at its California facility.

However, he warned that humanoid robots from China could pose potential competition, and believed that people outside China often underestimate the country.

Tesla's share price climbed 1.9% to US$439.76 in after-hours trading session.
~

AASTOCKS Financial News
Website: www.aastocks.com

After the bell on Wednesday, Meta (META.US) announced that its 4Q25 revenue rose by 24% YoY to USD59.89 billion, with an EPS of USD8.88, both beating expectations. Coupled with the higher-than-expected sales guidance it provided, its stock price soared more than 4% during after-hours trading.

In Meta's estimate, its 1Q26 sales will range from USD53.5 billion to USD56.5 billion, higher than the USD51.41 billion forecasted by analysts.
~



AAStocks Financial News
Web Site: www.aastocks.com

Tesla (TSLA.US) announced after the market closed on Wednesday that its net profit for 4Q25 slid 61% YoY to USD840 million, with adjusted EPS at US50 cents, exceeding the market expectation of US45 cents. Despite its first-ever annual revenue decline last year, the stock price swelled over 3% in after-hours trading.

For the quarter, revenue fell 3% YoY to USD24.9 billion, with the automotive segment slumping 11% to USD17.69 billion. The company had previously announced that fourth-quarter vehicle deliveries sank 16% YoY, and for the full year, they fell by 8.6%. For the entire year, revenue faded 3% to USD94.83 billion, marking the first annual revenue drop in the company's history.
~



AASTOCKS Financial News
Website: www.aastocks.com

Microsoft (MSFT.US) announced after the market close on Wednesday that its net profit for the second fiscal quarter ending last December mounted 60% YoY to USD38.46 billion, with adjusted EPS at USD4.14, topping market expectations of USD3.97. However, the growth in cloud service revenue was slightly worse than expectations, leading to a more than 4% slide in the stock price after hours.

During the quarter, revenue grew by 17% to USD81.27 billion, also surpassing the expected USD80.27 billion. Among these, revenue from Azure and other cloud services rallied 39%, lower than the 40% increase in the first fiscal quarter and slightly below the market expectation of a 39.4% upswing.
~



AASTOCKS Financial News
Website: www.aastocks.com

The Federal Reserve maintained interest rates unchanged, stating that US economic activity expanded stably and unemployment rate showed signs of stabilization. US bourse closed steady on Wednesday. The S&P 500 briefly hit a record high soon after the opening bell, crossing the 7,000-point mark for the first time, reaching a peak of 7,002. However, it closed slightly down by less than 1 point at 6,978. The Nasdaq added 40 points or 0.2% to 23,857. The DJIA held steady, slightly up by 12 points to 49,015.

NVIDIA (NVDA.US) may purportedly shift chip production to Intel (INTC.US). Intel rallied 11% at close, whereas NVIDIA rose 1.6%. Amazon (AMZN.US) confirmed the layoff of 16,000 employees and did not rule out further layoffs, with the stock initially growing but eventually closing down 0.7%.

Regarding earnings stocks, ASML (ASML.US) announced record-high orders, with its stock reaching a 52-week high before ebbing 2%. Storage infrastructure company Seagate (STX.US) reported second-quarter earnings and revenue beat, driven by strong AI data storage demand, which spurred a 19% surge in its stock price, making it the best performer among Nasdaq constituents.
~



AASTOCKS Financial News
Website: www.aastocks.com

Nvidia (NVDA.US) plans to shift its chip production from TSMC (TSM.US) to Intel (INTC.US) in 2028, foreign media reported. On Wednesday, Intel's stock price once mushroomed 12%, and last jumped up nearly 11%.

Under the pressure of US manufacturing policies and tariffs, major US chip manufacturers have long been exploring cooperation with Intel, the report cited insiders from the supply chain as saying.

However, due to the current limitations of the 18A technology, meaningful collaboration is likely to begin only after the mass production of the 14A chips in 2028.
~



AASTOCKS Financial News
Website: www.aastocks.com